To be sure, some Perrigo shareholders, including a number who plan to tender if Perrigo does not offer an alternative, have reservations about becoming Mylan shareholders, the sources said, citing corporate governance concerns raised by Mylan’s rejection of Teva. But according to the sources, a number of shareholders feel the structure of Mylan’s proposal could compel even hesitant shareholders to tender, in order to avoid becoming a marginalized minority in a Mylan-controlled company.
read more: http://www.haaretz.com/israel-news/business/1.678591